The Phase 3 trial for CagriSema aimed for 25% weight loss but only achieved 22.7%, which was not sufficient for Novo Nordisk's expectations.
Despite the shortcomings of the Phase 3 trial, Novo Nordisk remains committed to CagriSema and plans to submit for regulatory approval by the end of next year.
Eli Lilly's retatrutide demonstrated a competitive 24% weight loss in trials, further intensifying competition in the obesity drug market and affecting Novo Nordisk’s stock.
Martin Holst Lange expressed that CagriSema's weight loss profile shows superiority over existing treatments, hinting at future potential despite current trial setbacks.
Collection
[
|
...
]